Literature DB >> 10383128

Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.

G S Wu1, T F Burns, Y Zhan, E S Alnemri, W S El-Deiry.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors are members of the tumor necrosis factor superfamily. TRAIL selectively kills cancer cells but not normal cells. We report here the cloning of the mouse homologue of the TRAIL receptor KILLER/DR5 (MK). The cDNA of MK is 1146 bp in length and encodes a protein of 381 amino acids. MK contains an extracellular cysteine-rich domain, a transmembrane domain, and a cytoplasmic death-domain characteristic of Fas, tumor necrosis factor, and human TRAIL receptors. MK is highly homologous and binds TRAIL with similar affinity as human DR4 and KILLER/DR5. MK induces apoptosis in mouse and human cells and inhibits colony growth of NIH3T3 cells. Expression of MK is p53-dependent and up-regulated by tumor suppressor p53 and by DNA damaging agents in mouse cells undergoing apoptosis. This is the first report describing a mouse TRAIL receptor gene and also demonstrating that the p53-dependent regulation of KILLER/DR5-mediated apoptosis is conserved between human and mouse.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383128

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  93 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  TRAIL, Bim, and thymic-negative selection.

Authors:  Shi-Jun Zheng; Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Death receptor signal transducers: nodes of coordination in immune signaling networks.

Authors:  Nicholas S Wilson; Vishva Dixit; Avi Ashkenazi
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

4.  DR5 knockout mice are compromised in radiation-induced apoptosis.

Authors:  Niklas Finnberg; Joshua J Gruber; Peiwen Fei; Dorothea Rudolph; Anka Bric; Seok-Hyun Kim; Timothy F Burns; Hope Ajuha; Robert Page; Gen Sheng Wu; Youhai Chen; W Gillies McKenna; Eric Bernhard; Scott Lowe; Tak Mak; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

5.  Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.

Authors:  E W Duiker; E C F Dijkers; H Lambers Heerspink; S de Jong; A G J van der Zee; P L Jager; J G W Kosterink; E G E de Vries; M N Lub-de Hooge
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.

Authors:  Asim Saha; Sunil K Chatterjee; Kenneth A Foon; Malaya Bhattacharya-Chatterjee
Journal:  Immunology       Date:  2006-08       Impact factor: 7.397

7.  TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis.

Authors:  Jieqing Zhu; Longfei Chen; Juan Shi; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

8.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

Review 9.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

Review 10.  Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.

Authors:  Pedro P G Guimarães; Stephanie Gaglione; Tomasz Sewastianik; Ruben D Carrasco; Robert Langer; Michael J Mitchell
Journal:  ACS Nano       Date:  2018-02-06       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.